Insmed Stock Price, News & Analysis (NASDAQ:INSM)

$30.70 1.09 (3.68 %)
(As of 12/14/2017 03:28 PM ET)
Previous Close$29.61
Today's Range$29.75 - $30.99
52-Week Range$11.49 - $32.94
Volume849,000 shs
Average Volume683,484 shs
Market Capitalization$2.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.19

About Insmed (NASDAQ:INSM)

Insmed logoInsmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:INSM
CUSIPN/A
Phone+1-908-9779900

Debt

Debt-to-Equity Ratio0.13%
Current Ratio15.21%
Quick Ratio15.21%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.50 per share
Price / Book12.28

Profitability

Trailing EPS($3.12)
Net Income$-176,270,000.00
Net MarginsN/A
Return on Equity-100.23%
Return on Assets-70.48%

Miscellaneous

Employees161
Outstanding Shares76,590,000

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.03. View Insmed's Earnings History.

When will Insmed make its next earnings announcement?

Insmed is scheduled to release their next quarterly earnings announcement on Wednesday, February, 21st 2018. View Earnings Estimates for Insmed.

Where is Insmed's stock going? Where will Insmed's stock price be in 2017?

7 brokers have issued 1-year target prices for Insmed's stock. Their forecasts range from $17.00 to $54.00. On average, they anticipate Insmed's stock price to reach $36.71 in the next year. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Who are Insmed's key executives?

Insmed's management team includes the folowing people:

  • William H. Lewis, President, Chief Executive Officer, Director (Age 48)
  • Paolo Tombesi, Chief Financial Officer (Age 54)
  • S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services (Age 48)
  • Walter Perkins Ph.D., Chief Technology Officer
  • Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer (Age 52)
  • Mark Quigley, Vice President- Quality Assurance (Age 63)
  • Christine A. Pellizzari, General Counsel, Corporate Secretary (Age 49)
  • Roger Adsett, Chief Commercial Officer (Age 48)
  • Paul Streck, Chief Medical Officer (Age 54)
  • Donald J. Hayden Jr., Non-Executive Chairman of the Board (Age 61)

Who owns Insmed stock?

Insmed's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (5.17%), Orbimed Advisors LLC (2.45%), Emerald Advisers Inc. PA (1.38%), Emerald Mutual Fund Advisers Trust (1.11%), Victory Capital Management Inc. (0.92%) and C WorldWide Group Holding A S (0.58%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.

Who sold Insmed stock? Who is selling Insmed stock?

Insmed's stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Sectoral Asset Management Inc, Chartwell Investment Partners LLC and New York State Common Retirement Fund. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr, Melvin Md Sharoky and Myrtle S Potter. View Insider Buying and Selling for Insmed.

Who bought Insmed stock? Who is buying Insmed stock?

Insmed's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Victory Capital Management Inc., C WorldWide Group Holding A S, Alyeska Investment Group L.P., Ameriprise Financial Inc., Asymmetry Capital Management L.P., Sphera Funds Management LTD. and Point72 Asset Management L.P.. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed.

How do I buy Insmed stock?

Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of Insmed stock can currently be purchased for approximately $30.70.

How big of a company is Insmed?

Insmed has a market capitalization of $2.38 billion. The biopharmaceutical company earns $-176,270,000.00 in net income (profit) each year or ($3.12) on an earnings per share basis. Insmed employs 161 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Ave Bldg 10, BRIDGEWATER, NJ 08807-3365, United States. The biopharmaceutical company can be reached via phone at +1-908-9779900 or via email at [email protected]


MarketBeat Community Rating for Insmed (INSM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  184 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Insmed (NASDAQ:INSM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.882.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.13$35.13$35.13$22.75
Price Target Upside: 17.04% upside17.04% upside30.14% upside45.09% upside

Insmed (NASDAQ:INSM) Consensus Price Target History

Price Target History for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017HC WainwrightReiterated RatingBuy$35.00N/AView Rating Details
11/3/2017CowenReiterated RatingBuy$54.00N/AView Rating Details
9/6/2017Stifel NicolausReiterated RatingBuy$27.00 -> $43.00HighView Rating Details
9/6/2017Robert W. BairdReiterated RatingOutperform -> Positive$23.00 -> $32.00HighView Rating Details
9/5/2017Leerink SwannBoost Price TargetOutperform$27.00 -> $36.00HighView Rating Details
9/5/2017Evercore ISIBoost Price TargetOutperform -> Outperform$28.00 -> $40.00HighView Rating Details
6/11/2017CitigroupReiterated RatingNeutral$14.00 -> $17.00HighView Rating Details
8/21/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

Insmed (NASDAQ:INSM) Earnings History and Estimates Chart

Earnings by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018($0.68)N/AView Earnings Details
8/3/2017Q2 2017($0.63)($0.72)ViewListenView Earnings Details
5/3/2017Q1 2017($0.60)($0.60)$0.30 millionViewListenView Earnings Details
2/23/2017Q316($0.89)($1.10)$0.30 millionViewN/AView Earnings Details
11/3/2016Q216($0.59)($0.61)$0.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.56)($0.59)ViewN/AView Earnings Details
5/5/2016Q1($0.56)($0.54)ViewN/AView Earnings Details
2/25/2016Q415($0.49)($0.51)ViewN/AView Earnings Details
11/6/2015Q315($0.48)($0.50)ViewN/AView Earnings Details
8/6/2015Q2($0.48)($0.47)ViewN/AView Earnings Details
5/7/2015Q115($0.49)($0.55)ViewN/AView Earnings Details
2/27/2015Q414($0.57)($0.36)ViewN/AView Earnings Details
11/6/2014Q314($0.51)($0.54)ViewN/AView Earnings Details
8/6/2014Q214($0.50)($0.59)ViewN/AView Earnings Details
5/8/2014Q114($0.39)($0.36)ViewN/AView Earnings Details
3/6/2014Q413($0.45)($0.41)ViewN/AView Earnings Details
11/5/2013Q313($0.41)($0.46)ViewListenView Earnings Details
8/6/2013Q2 2013($0.32)($0.28)$5.38 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.46)($0.43)ViewListenView Earnings Details
11/7/2012Q312($0.42)($0.38)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Insmed (NASDAQ:INSM) Earnings Estimates

2017 EPS Consensus Estimate: ($2.40)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.58)($0.58)($0.58)
Q2 20171($0.63)($0.63)($0.63)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.60)($0.60)($0.60)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Insmed (NASDAQ:INSM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insmed (NASDAQ INSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.03%
Institutional Ownership Percentage: 95.29%
Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/14/2017Donald J Hayden JrDirectorSell15,000$32.50$487,500.00View SEC Filing  
9/7/2017Donald J Hayden JrDirectorSell45,000$29.67$1,335,150.00View SEC Filing  
9/6/2017Melvin Md SharokyDirectorSell50,000$27.37$1,368,500.00View SEC Filing  
5/31/2017Christine A PellizzariGeneral CounselBuy10,000$15.14$151,400.00View SEC Filing  
12/15/2016Christine A PellizzariGeneral CounselBuy20,000$12.81$256,200.00View SEC Filing  
12/14/2016Myrtle S PotterDirectorSell6,466$12.79$82,700.14View SEC Filing  
11/14/2016Andrew T DrechslerCFOSell45,000$14.67$660,150.00View SEC Filing  
11/9/2016Orlov S Nicole SchaefferSVPSell68,774$11.95$821,849.30View SEC Filing  
2/1/2016William LewisCEOBuy50,000$13.34$667,000.00View SEC Filing  
9/2/2015Donald J. Hayden, Jr.DirectorSell25,000$24.06$601,500.00View SEC Filing  
5/12/2015Mark QuigleyVPSell18,750$22.07$413,812.50View SEC Filing  
8/13/2014Melvin Md SharokyDirectorBuy88,889$11.25$1,000,001.25View SEC Filing  
11/1/2013William LewisCEOBuy5,233$14.28$74,727.24View SEC Filing  
7/22/2013Fmr LlcInsiderSell158,758$12.02$1,908,271.16View SEC Filing  
7/18/2013Fmr LlcInsiderSell310,227$11.49$3,564,508.23View SEC Filing  
7/15/2013Fmr LlcInsiderSell161,531$10.79$1,742,919.49View SEC Filing  
7/9/2013Fmr LlcInsiderSell146,599$10.01$1,467,455.99View SEC Filing  
7/3/2013Fmr LlcInsiderSell365,779$9.96$3,643,158.84View SEC Filing  
7/1/2013William LewisCEOBuy7,585$9.83$74,560.55View SEC Filing  
6/24/2013Fmr LlcInsiderSell50,000$12.00$600,000.00View SEC Filing  
6/20/2013Fmr LlcInsiderSell143,088$12.24$1,751,397.12View SEC Filing  
6/12/2013Fmr LlcInsiderSell85,758$13.00$1,114,854.00View SEC Filing  
6/6/2013Fmr LlcInsiderSell130,557$12.85$1,677,657.45View SEC Filing  
4/1/2013William LewisCEOBuy9,816$7.58$74,405.28View SEC Filing  
1/9/2013William LewisCEOBuy10,770$6.90$74,313.00View SEC Filing  
12/3/2012William LewisCEOBuy13,568$7.36$99,860.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Insmed (NASDAQ INSM) News Headlines

Source:
DateHeadline
Barrons After Hours: Insmed Soars, Western Digital Jumps, VeriFone SlumpsBarron's After Hours: Insmed Soars, Western Digital Jumps, VeriFone Slumps
finance.yahoo.com - December 13 at 8:49 AM
 Brokerages Expect Insmed, Inc. (INSM) to Announce -$0.66 EPS Brokerages Expect Insmed, Inc. (INSM) to Announce -$0.66 EPS
www.americanbankingnews.com - December 4 at 11:26 PM
Insmed, Inc. (INSM) Receives Consensus Recommendation of "Hold" from BrokeragesInsmed, Inc. (INSM) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 4 at 1:56 AM
Today’s Research Reports on Stocks to Watch: Horizon Pharma and Insmed IncorporatedToday’s Research Reports on Stocks to Watch: Horizon Pharma and Insmed Incorporated
finance.yahoo.com - December 1 at 11:45 AM
Insmed, Inc. Fundamental Analysis : November 30, 2017Insmed, Inc. Fundamental Analysis : November 30, 2017
finance.yahoo.com - December 1 at 11:45 AM
Insmed to Present at the Nasdaq 37th Annual Investor ConferenceInsmed to Present at the Nasdaq 37th Annual Investor Conference
finance.yahoo.com - November 28 at 9:37 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
finance.yahoo.com - November 23 at 2:24 AM
Today’s Research Reports on Stocks to Watch: Juno Therapeutics and Insmed IncorporatedToday’s Research Reports on Stocks to Watch: Juno Therapeutics and Insmed Incorporated
finance.yahoo.com - November 17 at 7:01 AM
Donald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) StockDonald J. Hayden, Jr. Sells 15,000 Shares of Insmed, Inc. (INSM) Stock
www.americanbankingnews.com - November 16 at 4:24 PM
Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)Technical Reports on Biotech Equities -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)
www.prnewswire.com - November 11 at 12:38 PM
Implied Volatility Surging for Insmed Incorporated (INSM) Stock OptionsImplied Volatility Surging for Insmed Incorporated (INSM) Stock Options
finance.yahoo.com - November 11 at 12:38 PM
3 Companies Spearheading the Antibiotics Space in 20183 Companies Spearheading the Antibiotics Space in 2018
finance.yahoo.com - November 11 at 12:38 PM
Savaras (SVRA) CEO Rob Neville on Q3 2017 Results - Earnings Call TranscriptSavara's (SVRA) CEO Rob Neville on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 9 at 6:51 AM
Insmed to Present at Two November ConferencesInsmed to Present at Two November Conferences
finance.yahoo.com - November 9 at 6:51 AM
Insmed, Inc. (INSM) Receives Average Recommendation of "Hold" from BrokeragesInsmed, Inc. (INSM) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 9 at 1:34 AM
Todays Research Reports on Trending Tickers: Insmed Inc. and Sarepta TherapeuticsToday's Research Reports on Trending Tickers: Insmed Inc. and Sarepta Therapeutics
finance.yahoo.com - November 7 at 4:33 AM
Asymmetry Capital Management, LP Buys Insmed Inc, Ionis Pharmaceuticals Inc, HMS Holdings ... - NasdaqAsymmetry Capital Management, LP Buys Insmed Inc, Ionis Pharmaceuticals Inc, HMS Holdings ... - Nasdaq
www.nasdaq.com - November 6 at 12:41 AM
Head-To-Head Review: Insmed (INSM) vs. Intec Pharma (NTEC)Head-To-Head Review: Insmed (INSM) vs. Intec Pharma (NTEC)
www.americanbankingnews.com - November 5 at 3:26 AM
Insmed, Inc. (INSM) Stock Rating Reaffirmed by Cowen and CompanyInsmed, Inc. (INSM) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - November 3 at 7:50 PM
Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Insmed Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 3 at 10:15 AM
Insmed Incorporated to Host Earnings CallInsmed Incorporated to Host Earnings Call
finance.yahoo.com - November 3 at 10:15 AM
Insmed Reports Third Quarter 2017 Financial Results and Provides Business UpdateInsmed Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 3 at 10:15 AM
Insmed reports 3Q lossInsmed reports 3Q loss
finance.yahoo.com - November 3 at 10:15 AM
Edited Transcript of INSM earnings conference call or presentation 2-Nov-17 12:30pm GMTEdited Transcript of INSM earnings conference call or presentation 2-Nov-17 12:30pm GMT
finance.yahoo.com - November 3 at 10:15 AM
Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017Insmed to Host Third Quarter 2017 Financial Results Conference Call on Thursday, November 2, 2017
finance.yahoo.com - October 26 at 2:04 PM
Insmed, Inc. (INSM) Scheduled to Post Earnings on ThursdayInsmed, Inc. (INSM) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - October 26 at 5:26 AM
Insmed, Inc. (INSM) Receives Consensus Recommendation of "Buy" from AnalystsInsmed, Inc. (INSM) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - October 15 at 2:28 AM
Insmed Stock Sees Short Interest Increase 14.4%Insmed Stock Sees Short Interest Increase 14.4%
www.thestreet.com - October 12 at 6:27 AM
Stocks Under Scanner in the Biotech Space -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)Stocks Under Scanner in the Biotech Space -- ImmunoGen, Incyte, Infinity Pharma, and Insmed - PR Newswire (press release)
www.prnewswire.com - October 5 at 8:45 AM
BRIEF-Arsanis appoints Michael Gray as chief financial officerBRIEF-Arsanis appoints Michael Gray as chief financial officer
www.reuters.com - October 4 at 5:47 PM
Best Sector ETF of Q3 and its Top-Performing StocksBest Sector ETF of Q3 and its Top-Performing Stocks
finance.yahoo.com - October 2 at 1:07 PM
Insmed Incorporated (INSM) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowInsmed Incorporated (INSM) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 26 at 5:01 PM
Commit To Purchase Insmed At $18, Earn 9.3% Annualized Using OptionsCommit To Purchase Insmed At $18, Earn 9.3% Annualized Using Options
www.nasdaq.com - September 22 at 1:48 PM
Insmed Incorporated (INSM) Receives Average Rating of "Buy" from AnalystsInsmed Incorporated (INSM) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - September 20 at 2:30 AM
Insmed to Present at Two September Investor Conferences - GlobeNewswire (press release)Insmed to Present at Two September Investor Conferences - GlobeNewswire (press release)
globenewswire.com - September 19 at 7:58 PM
Insmed to Present at Two September Investor ConferencesInsmed to Present at Two September Investor Conferences
finance.yahoo.com - September 19 at 7:58 PM
 Analysts Expect Insmed, Inc. (INSM) Will Announce Earnings of -$0.69 Per Share Analysts Expect Insmed, Inc. (INSM) Will Announce Earnings of -$0.69 Per Share
www.americanbankingnews.com - September 19 at 10:46 AM
As Insmed Reaches New Highs, Is Matinas Following in Its Footsteps?As Insmed Reaches New Highs, Is Matinas Following in Its Footsteps?
finance.yahoo.com - September 13 at 2:52 AM
Insmed Announces Closing of Public OfferingInsmed Announces Closing of Public Offering
finance.yahoo.com - September 11 at 8:38 PM
Insmed Prices Offering At $28.50/ShareInsmed Prices Offering At $28.50/Share
www.rttnews.com - September 8 at 11:31 PM
Insmed prices public offering of common stockInsmed prices public offering of common stock
seekingalpha.com - September 7 at 8:10 PM
Insider Selling: Insmed, Inc. (INSM) Director Sells 45,000 Shares of StockInsider Selling: Insmed, Inc. (INSM) Director Sells 45,000 Shares of Stock
www.americanbankingnews.com - September 7 at 7:22 PM
Insider Selling: Insmed, Inc. (INSM) Director Sells 50,000 Shares of StockInsider Selling: Insmed, Inc. (INSM) Director Sells 50,000 Shares of Stock
www.americanbankingnews.com - September 7 at 7:20 PM
FY2018 EPS Estimates for Insmed, Inc. Cut by Analyst (INSM)FY2018 EPS Estimates for Insmed, Inc. Cut by Analyst (INSM)
www.americanbankingnews.com - September 7 at 1:36 PM
Insmeds inhalable amikacin successful in late-stage study - Seeking AlphaInsmed's inhalable amikacin successful in late-stage study - Seeking Alpha
seekingalpha.com - September 7 at 12:54 AM
Benzingas Option Alert Recap From September 6 - BenzingaBenzinga's Option Alert Recap From September 6 - Benzinga
www.benzinga.com - September 7 at 12:54 AM
UPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy - MarketWatchUPDATED: Insmed shares skyrocket 130% on positive late-stage results for rare lung disease therapy - MarketWatch
www.marketwatch.com - September 7 at 12:54 AM
Insmed Announces Pricing of Public Offering of Common StockInsmed Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 7 at 12:54 AM
Insmed Inc. (INSM) Vaulted To A New High On Phase 3 Study ResultsInsmed Inc. (INSM) Vaulted To A New High On Phase 3 Study Results
www.rttnews.com - September 6 at 7:54 PM
Insmed (INSM) Top-line Data Indicates Phase 3 CONVERT Trial Met Primary Endpoint of Culture Conversion - SlideshowInsmed (INSM) Top-line Data Indicates Phase 3 CONVERT Trial Met Primary Endpoint of Culture Conversion - Slideshow
seekingalpha.com - September 6 at 7:53 PM

SEC Filings

Insmed (NASDAQ:INSM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Insmed (NASDAQ:INSM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Insmed (NASDAQ INSM) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.